RepliCel Life Sciences (RepliCel Life Sciences) 3-Year FCF Growth Rate : 31.50% (As of Sep. 2023)

View and export this data going back to 2004. Start your Free Trial

What is RepliCel Life Sciences 3-Year FCF Growth Rate?

RepliCel Life Sciences's Free Cash Flow per Share for the three months ended in Sep. 2023 was $-0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 31.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of RepliCel Life Sciences was 54.00% per year. The lowest was -107.70% per year. And the median was 7.10% per year.

Competitive Comparison of RepliCel Life Sciences's 3-Year FCF Growth Rate

For the Biotechnology subindustry, RepliCel Life Sciences's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RepliCel Life Sciences's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RepliCel Life Sciences's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where RepliCel Life Sciences's 3-Year FCF Growth Rate falls into.

RepliCel Life Sciences 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

RepliCel Life Sciences (OTCPK:REPCF) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

RepliCel Life Sciences 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of RepliCel Life Sciences's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

RepliCel Life Sciences (RepliCel Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RepliCel Life Sciences Inc (OTCPK:REPCF) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

P6P2:Germany P6P2:Germany RP:Canada

Address

570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1

Website

https://www.replicel.com

RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from Licensing fees.